Rajkumar, Chakravarthi, Ali, Khalid and Parekh, Nikesh (2018) Frailty predicts medication-related harm requiring healthcare: a UK multicentre prospective cohort study. In: 14th International Congress of the European Geriatric Medicine Society: Advancing Geriatric Medicine in a Modern World, 10th - 12th October 2018, Berlin.
![]() |
PDF
- Accepted Version
Download (78kB) |
Abstract
Introduction
Frailty has been under investigated as a risk factor for medication-related harm (MRH) in older adults[1]. We sought to determine whether frailty is independently associated with MRH in a large multicentre prospective cohort, the PRIME study.
Methods
The PRIME study recruited 1280 older adults at hospital discharge from 5 hospitals in England between 2013 to 2015[2]. MRH and associated healthcare use within 8-weeks post-discharge were identified by senior pharmacists using (1) hospital readmission data, (2) primary care records, (3) patient telephone interviews. Based on the Rockwood approach[3], we developed a frailty index including 55 deficits from multiple domains (morbidity, cognition, mood, strength and mobility, nutrition, daily function). Frailty was defined using the established cut-off of 20% deficits[4], and internally validated using Kaplan-Meier plots comparing survival in frail and non-frail patients. We then used logistic regression analysis to investigate the relationship between frailty and MRH requiring healthcare.
Results
1116 patients completed follow-up (median age 81.9 years, range 65-103 years, 58.4% female). 446 patients (40%) were frail in our cohort. 36% of frail patients experienced MRH compared with 25% in non-frail patients. There was a strong relationship between frailty and MRH (OR 1.67, 95% CI 1.29-2.17, p<0.001). A significant relationship between frailty and MRH remained on multivariable regression, adjusting for polypharmacy, age and gender (OR 1.37, 95% CI 1.04-1.81, p=0.027). Frail patients had significantly reduced 18-month survival (Log-Rank test p<0.001).
Key Conclusions
Frailty is a predictor of MRH requiring healthcare, independent of polypharmacy.
Item Type: | Conference or Workshop Item (Poster) |
---|---|
Schools and Departments: | Brighton and Sussex Medical School > Brighton and Sussex Medical School Brighton and Sussex Medical School > Clinical and Experimental Medicine |
Depositing User: | Marie Shelton |
Date Deposited: | 27 Jul 2018 14:38 |
Last Modified: | 06 May 2021 09:41 |
URI: | http://sro.sussex.ac.uk/id/eprint/77388 |
View download statistics for this item
📧 Request an update